Kara A Michels1, Louise A Brinton1, Nicolas Wentzensen1, Kathy Pan2, Chu Chen3, Garnet L Anderson3, Ruth M Pfeiffer1, Xia Xu4, Thomas E Rohan5, Britton Trabert1. 1. Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD. 2. Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA. 3. Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA. 4. Cancer Research Technology Program, Leidos Biomedical Research, Inc, Frederick National Laboratory for Cancer Research, Frederick, MD. 5. Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY (TER).
Abstract
BACKGROUND: After menopause, several androgens continue to be produced primarily by the adrenal glands; these can be converted into estrogens via aromatization or into androgen metabolites. It is unclear if androgens are associated with endometrial cancer risk independently of their being precursors to estrogens or if alternative metabolic pathways influence risk. METHODS: We measured prediagnostic serum concentrations of 12 androgens and their metabolites using highly sensitive liquid chromatography-tandem mass spectrometry assays in a nested case-control study of postmenopausal women from the Women's Health Initiative Observational Study (313 endometrial cancer case subjects, 354 matched control subjects). Estrogens were previously assayed. We used conditional logistic regression to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for endometrial cancer with adjustment for confounders. RESULTS: Compared to the lowest concentrations, the highest levels of adrenal androgens were associated with increased endometrial cancer risk: dehydroepiandrosterone (5th vs 1st quintile: OR = 1.85, 95% CI = 1.06 to 3.25), androstenedione (OR = 2.36, 95% CI = 1.34 to 4.16), and testosterone (OR = 1.91, 95% CI = 1.12 to 3.24). Downstream androgen metabolites were not associated with endometrial cancer. Although increased risks for the parent androgens were still suggested after adjustment for unconjugated estradiol, the associations attenuated, and with the exception of androstenedione, were no longer statistically significant. We also evaluated ratios of estrogens relative to their androgenic precursors; both higher unconjugated estrone:androstenedione and higher unconjugated estradiol:testosterone were associated with increased endometrial cancer risk. CONCLUSIONS: We identified increased risks for endometrial cancer with the highest levels of adrenal androgens and high levels of estrogens relative to these androgens. As adrenal androgens can be aromatized to estrogens, this suggests androgens likely influence endometrial carcinogenesis via estrogen metabolism.
BACKGROUND: After menopause, several androgens continue to be produced primarily by the adrenal glands; these can be converted into estrogens via aromatization or into androgen metabolites. It is unclear if androgens are associated with endometrial cancer risk independently of their being precursors to estrogens or if alternative metabolic pathways influence risk. METHODS: We measured prediagnostic serum concentrations of 12 androgens and their metabolites using highly sensitive liquid chromatography-tandem mass spectrometry assays in a nested case-control study of postmenopausal women from the Women's Health Initiative Observational Study (313 endometrial cancer case subjects, 354 matched control subjects). Estrogens were previously assayed. We used conditional logistic regression to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for endometrial cancer with adjustment for confounders. RESULTS: Compared to the lowest concentrations, the highest levels of adrenal androgens were associated with increased endometrial cancer risk: dehydroepiandrosterone (5th vs 1st quintile: OR = 1.85, 95% CI = 1.06 to 3.25), androstenedione (OR = 2.36, 95% CI = 1.34 to 4.16), and testosterone (OR = 1.91, 95% CI = 1.12 to 3.24). Downstream androgen metabolites were not associated with endometrial cancer. Although increased risks for the parent androgens were still suggested after adjustment for unconjugated estradiol, the associations attenuated, and with the exception of androstenedione, were no longer statistically significant. We also evaluated ratios of estrogens relative to their androgenic precursors; both higher unconjugated estrone:androstenedione and higher unconjugated estradiol:testosterone were associated with increased endometrial cancer risk. CONCLUSIONS: We identified increased risks for endometrial cancer with the highest levels of adrenal androgens and high levels of estrogens relative to these androgens. As adrenal androgens can be aromatized to estrogens, this suggests androgens likely influence endometrial carcinogenesis via estrogen metabolism.
Authors: J David Curb; Anne McTiernan; Susan R Heckbert; Charles Kooperberg; Janet Stanford; Michael Nevitt; Karen C Johnson; Lori Proulx-Burns; Lisa Pastore; Michael Criqui; Sandra Daugherty Journal: Ann Epidemiol Date: 2003-10 Impact factor: 3.797
Authors: Robert D Langer; Emily White; Cora E Lewis; Jane M Kotchen; Susan L Hendrix; Maurizio Trevisan Journal: Ann Epidemiol Date: 2003-10 Impact factor: 3.797
Authors: Annekatrin Lukanova; Eva Lundin; Andrea Micheli; Alan Arslan; Pietro Ferrari; Sabina Rinaldi; Vittorio Krogh; Per Lenner; Roy E Shore; Carine Biessy; Paola Muti; Elio Riboli; Karen L Koenig; Mortimer Levitz; Pär Stattin; Franco Berrino; Göran Hallmans; Rudolf Kaaks; Paolo Toniolo; Anne Zeleniuch-Jacquotte Journal: Int J Cancer Date: 2004-01-20 Impact factor: 7.396
Authors: Xia Xu; John M Roman; Haleem J Issaq; Larry K Keefer; Timothy D Veenstra; Regina G Ziegler Journal: Anal Chem Date: 2007-09-12 Impact factor: 6.986
Authors: Louise A Brinton; Cher M Dallal; Britton Trabert; Ashley M Geczik; Doug C Bauer; Diana S M Buist; Jane A Cauley; Roni T Falk; Gretchen L Gierach; Trisha F Hue; James V Lacey; Andrea Z LaCroix; Kara A Michels; Jeffrey A Tice; Xia Xu Journal: Cancer Epidemiol Biomarkers Prev Date: 2021-08-31 Impact factor: 4.090
Authors: Hannah Oh; Robert A Wild; JoAnn E Manson; Jennifer W Bea; Aladdin H Shadyab; Ruth M Pfeiffer; Nazmus Saquib; Lisa Underland; Garnet L Anderson; Xia Xu; Britton Trabert Journal: Cancer Epidemiol Biomarkers Prev Date: 2021-08-26 Impact factor: 4.090
Authors: Hannah Oh; Nazmus Saquib; Heather M Ochs-Balcom; Ruth M Pfeiffer; Phyllis A Richey; Aladdin H Shadyab; Robert A Wild; Lisa Underland; Garnet L Anderson; Xia Xu; Britton Trabert Journal: Cancer Epidemiol Biomarkers Prev Date: 2021-10-18 Impact factor: 4.090
Authors: Lauren M Hurwitz; Aladdin H Shadyab; Fred K Tabung; Garnet L Anderson; Nazmus Saquib; Robert B Wallace; Robert A Wild; Ruth M Pfeiffer; Xia Xu; Britton Trabert Journal: Cancer Prev Res (Phila) Date: 2022-03-01